Incidence of Drug Induced Hepatotoxicity During Intensive Phase of Antitubercular Therapy in Rural Population of Uttar Pradesh

Abstract

Introduction
Tuberculosis (TB) is the most common cause of infection-related death worldwide. The most frequent adverse effects of antituberculosis treatment are hepatotoxicity, skin reactions, gastrointestinal and neurological disorders.
Hepatic drug reactions usually occur in the first 2 months of treatment but may happen at any moment during the treatment period.
Aims & Objectives:
• To identify eligible case to start Anti Tubercular therapy.
• Serial monitoring and documentation of liver functions during intensive phase of therapy.
• To compare the variables in hepatic derangement group and normal group after introduction of ATT.
Materials & methods: This study was an observational prospective cohort (analytical) study carried out in the pediatric ward of U.P.U.M.S. Saifai, a tertiary care centre of 1200 beds between Jan2015-june 2016
All the patients admitted in pediatric ward with Tuberculosis were interviewed and informed,written consent was obtained. Relevant clinical history and clinical examination was performed on each of participants with emphasis on anthropometry (height, weight, mid upper arm circumference), axillary temperature, general physical examination, respiratory system examined thoroughly. Systemic examination and specific investigations including Liver function test were done
Result: In our study, the incidence of anti-TB-DIH was 15%, with 16 out of 107 children demonstrating clinical or biochemical features of liver injury.
Conclusion: This study reinforces that anti-TB DIH is a clinically significant complication in children, with a 15% incidence and early onset in most cases. Male gender was identified as a potential risk factor, while extrapulmonary TB and malnutrition were not significant predictors in our setting.